- Home
- XERS vs BBAI Comparison
XERS vs BBAI Comparison
Compare XERS & BBAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | XERS | BBAI |
|---|---|---|
| Founded | 2005 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | EDP Services |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.4B |
| IPO Year | 2021 | 2021 |
Fundamental Metrics
Financial Performance| Metric | XERS | BBAI |
|---|---|---|
| Price | $10.51 | $2.39 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 7 | 2 |
| Target Price | ★ $12.86 | $4.00 |
| AVG Volume (30 Days) | 2.3M | ★ 13.1M |
| Earning Date | 11-05-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 100.00 | 35.43 |
| EPS | N/A | N/A |
| Revenue | $49,590,000.00 | ★ $127,672,000.00 |
| Revenue This Year | $32.91 | $13.84 |
| Revenue Next Year | $23.75 | $10.77 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 142.67 | N/A |
| 52 Week Low | $5.25 | $2.34 |
| 52 Week High | $10.35 | $9.39 |
Technical Indicators
Market Signals| Indicator | XERS | BBAI |
|---|---|---|
| Relative Strength Index (RSI) | 69.93 | 25.79 |
| Support Level | $7.15 | N/A |
| Resistance Level | N/A | $2.90 |
| Average True Range (ATR) | 0.52 | 0.10 |
| MACD | 0.13 | -0.03 |
| Stochastic Oscillator | 99.03 | 6.18 |
Price Performance
Historical ComparisonAbout XERS Xeris Biopharma Holdings Inc.
Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.
About BBAI BigBear.ai Inc.
BigBear.ai Holdings Inc is a provider of mission-ready artificial intelligence (AI) technology originally founded to serve defense and national security mission customers. The Company provides Edge AI-powered decision intelligence solutions, including artificial intelligence and machine learning, generative AI, data science, computer vision, biometrics, cyber, cloud solutions, and systems integration. Customers rely on its predictive analytics capabilities in mission-based operating environments. Its solutions are organized into five markets, including Supply Chain & Logistics Solutions, Cybersecurity Solutions, Autonomous Systems Solutions, Digital Identity Services, and the Ask Sage Platform.